MARK L SILVERBERG, M.D.
Medical Practice at Pueblo St, Santa Barbara, CA
License number
California A68355
Category
Medical Practice
Type
Ophthalmology
Address
Address
317 W Pueblo St, Santa Barbara, CA 93105
Phone
(805) 681-1761
(805) 681-1768 (Fax)
(805) 681-1768 (Fax)
Organization information
See more information about MARK L SILVERBERG at bizstanding.comSansum Clinic - Mark L Silverberg MD
4151B Foothill Rd, Santa Barbara, CA 93110
Categories:
Ophthalmology Physicians & Surgeons, Physicians & Surgeons
Phone:
(805) 681-8950 (Phone)
Professional information
Dr. Mark L Silverberg, Santa Barbara CA - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
Sansum Clinic, Ophthalmology
29 W Anapamu St, Santa Barbara 93101
(805) 681-8950 (Phone)
29 W Anapamu St, Santa Barbara 93101
(805) 681-8950 (Phone)
Certifications:
Ophthalmology, 2000
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Sansum Clinic, Ophthalmology
29 W Anapamu St, Santa Barbara 93101
Santa Barbara Cottage Hospital
400 West Pueblo St, Santa Barbara 93105
29 W Anapamu St, Santa Barbara 93101
Santa Barbara Cottage Hospital
400 West Pueblo St, Santa Barbara 93105
Education:
Medical School
University Of California, San Francisco, School Of Medicine
Graduated: 1995
Santa Barbara Cottage Hospital
Graduated: 1996
Manhattan Eye Ear and Throat
Graduated: 1999
UCLA Jules Stein
Graduated: 2000
University Of California, San Francisco, School Of Medicine
Graduated: 1995
Santa Barbara Cottage Hospital
Graduated: 1996
Manhattan Eye Ear and Throat
Graduated: 1999
UCLA Jules Stein
Graduated: 2000
Compositions And Methods For Non-Surgical Treatment Of Ptosis
US Patent:
2012022, Sep 6, 2012
Filed:
Feb 29, 2012
Appl. No.:
13/408364
Inventors:
Mark Silverberg - Santa Barbara CA, US
Assignee:
VOOM, LLC - Santa Barbara CA
International Classification:
A61K 31/4174, A61P 21/00, A61P 27/02
US Classification:
514401
Abstract:
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Compositions And Methods For Non-Surgical Treatment Of Ptosis
US Patent:
2012022, Sep 6, 2012
Filed:
Aug 26, 2011
Appl. No.:
13/218584
Inventors:
Mark Silverberg - Santa Barbara CA, US
Assignee:
VOOM, LLC - Santa Barbara CA
International Classification:
A61K 31/4174, A61K 31/137, A61P 21/00
US Classification:
514401, 514653
Abstract:
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Compositions And Methods For Non-Surgical Treatment Of Ptosis
US Patent:
8357714, Jan 22, 2013
Filed:
Oct 11, 2011
Appl. No.:
13/270577
Inventors:
Mark Silverberg - Santa Barbara CA, US
Assignee:
Voom, LLC - Santa Barbara CA
International Classification:
A61K 31/415
US Classification:
514396
Abstract:
Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0. 1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.